Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
Arrowhead Pharmaceuticals (ARWR) Ownership Overview
4.55% Insiders
20.08% Mutual Funds
0.09% Other Institutional Investors
24.85% ETFs
50.44% Public Companies and Individual Investors
The ownership structure of Arrowhead Pharmaceuticals (ARWR) stock is a mix of institutional, retail, and individual investors. Approximately 45.01% of the company’s stock is owned by Institutional Investors, 4.55% is owned by Insiders, and 50.44% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jan 07, 2025 | xxxxxxxxxxxxx | $196900 | |
| Apr 03, 2024 | James C Hamilton Chief Discovery/trans Medicine | xxxxxxxxxxxxx | $168180 |
| Mar 20, 2024 | Hongbo Lu Director | xxxxxxxxxxxxx | $82990 |
| Mar 08, 2024 | xxxxxxxxxxxxx | $1407600 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2024 | xxxxxxxxxxxxx | $512123 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $2368176 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $16770429 | |
| Sep 30, 2024 | xxxxxxxxxxxxx | $94622450 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,795,438 | Institution | 11.09% | 261,147,641 | |
| 11,567,856 | Institution | 9.30% | 218,979,514 | |
| 10,177,542 | Institution | 8.18% | 192,660,870 | |
| 4,885,000 | Institution | 3.93% | 92,473,050 | |
| 3,783,251 | Institution | 3.04% | 71,616,941 | |
| 3,764,252 | Insider | 3.03% | 71,257,290 | |
| 1,422,566 | Institution | 1.14% | 26,929,174 | |
| 1,321,131 | Institution | 1.06% | 25,009,010 | |
| 1,301,965 | Institution | 1.05% | 24,646,197 | |
| 1,222,835 | Institution | 0.98% | 23,148,267 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 10,177,542 | Institution | 8.18% | 192,660,870 | |
| 1,422,566 | Institution | 1.14% | 26,929,174 | |
| 1,321,131 | Institution | 1.06% | 25,009,010 | |
| 1,301,965 | Institution | 1.05% | 24,646,197 | |
| 1,222,835 | Institution | 0.98% | 23,148,267 | |
| 1,109,494 | Institution | 0.89% | 21,002,721 | |
| 807,099 | Institution | 0.65% | 15,278,384 | |
| 694,370 | Institution | 0.56% | 13,144,424 | |
| 661,739 | Institution | 0.53% | 12,526,719 | |
| 606,280 | Institution | 0.49% | 11,476,880 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,040,208 | Institution | 3.25% | 76,481,137 | |
| 3,658,560 | Institution | 2.94% | 95,232,317 | |
| 3,364,205 | Institution | 2.70% | 79,798,943 | |
| 3,179,652 | Institution | 2.56% | 60,190,812 | |
| 2,976,070 | Institution | 2.39% | 77,467,102 | |
| 1,889,936 | Institution | 1.52% | 49,195,034 | |
| 1,636,904 | Institution | 1.32% | 42,608,611 | |
| 1,511,608 | Institution | 1.21% | 27,284,524 | |
| 1,094,069 | Institution | 0.88% | 20,710,726 | |
| 1,007,427 | Institution | 0.81% | 19,070,593 |
FAQ
Who Owns Arrowhead Pharmaceuticals (ARWR)?
According to the latest TipRanks data, approximately 0.09% of the company's stock is held by institutional investors, 4.55% is held by insiders, and 50.44% is held by retail investors.
What percentage of Arrowhead Pharmaceuticals (ARWR) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.09% of Arrowhead Pharmaceuticals (ARWR) stock is held by institutional investors.
What percentage of Arrowhead Pharmaceuticals (ARWR) stock is held by retail investors?
According to the latest TipRanks data, approximately 50.44% of Arrowhead Pharmaceuticals (ARWR) stock is held by retail investors.
Who owns the most shares of Arrowhead Pharmaceuticals (ARWR)?
iShares owns the most shares of Arrowhead Pharmaceuticals (ARWR).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.